Overview

A Phase 1b Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SR419

Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This study is to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SR419 in Patients with Peripheral Neuropathic Pain
Phase:
Phase 1
Details
Lead Sponsor:
SIMR (Australia) Biotech Pty Ltd
SIMR (Australia) Biotech Pty Ltd.